文献速递间质性肺疾病肺栓塞与肺血管病

吸入曲前列尼尔对间质性肺病相关肺高压患者FVC的影响:INCREASE研究事后分析

Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study.
PubMed 文献 · Lancet Respir Med · 2021-06-29

INCREASE是一项随机、安慰剂对照的3期试验,评估吸入曲前列尼尔治疗间质性肺病(ILD)相关肺高压的疗效。

要点

  • 常见不良事件包括咳嗽、头痛、呼吸困难、头晕、恶心、疲劳和腹泻。

核心结论

  • 在ILD相关肺高压患者中,吸入曲前列尼尔与16周时FVC改善相关,尤其在特发性间质性肺炎、特别是特发性肺纤维化患者中更明显。

研究设计与样本

  • INCREASE研究的事后分析,纳入326例18岁及以上、经胸部CT诊断ILD且伴肺高压的患者,分析基于意向治疗人群。

主要发现

  • 最常见不良事件包括咳嗽、头痛、呼吸困难、头晕、恶心、疲劳和腹泻。

临床怎么用

  • 对于ILD相关肺高压患者,吸入曲前列尼尔可能改善FVC,尤其在特发性肺纤维化患者中需进一步前瞻性研究验证。

局限性

  • 本分析为事后分析,FVC绝对变化未达统计学显著性,特发性肺纤维化亚组结果需前瞻性随机对照研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: INCREASE was a randomised, placebo-controlled, phase 3 trial that evaluated inhaled treprostinil in patients with interstitial lung disease (ILD) and associated pulmonary hypertension. Treprostinil improved exercise capacity from baseline to week 16, assessed with the use of a 6-min walk test, compared with placebo. Improvements in forced vital capacity (FVC) were also reported. The aim of this post-hoc analysis was to further characterise the effects of inhaled treprostinil on FVC in the overall study population and in various subgroups of interest. METHODS: In this post-hoc analysis, we evaluated FVC changes in the overall study population and in various subgroups defined by cause of disease or baseline clinical parameters. The study population included patients aged 18 years and older who had a diagnosis of ILD based on evidence of diffuse parenchymal lung disease on chest CT done within 6 months before random assignment (not centrally adjudicated). All analyses were done on the intention-to-treat population, defined as individuals who were randomly assigned and received at least one dose of study drug. The INCREASE study is registered with ClinicalTrials.gov, NCT02630316. FINDINGS: Between Feb 3, 2017, and Aug 30, 2019, 326 patients were enrolled in the INCREASE trial. Inhaled treprostinil was associated with a placebo-corrected least squares mean improvement in FVC of 28·5 mL (SE 30·1; 95% CI -30·8 to 87·7; p=0·35) at week 8 and 44·4 mL (35·4; -25·2 to 114·0; p=0·21) at week 16, with associated percentage of predicted FVC improvements of 1·8% (0·7; 0·4 to 3·2; p=0·014) and 1·8% (0·8; 0·2 to 3·4; p=0·028). Subgroup analysis of patients with idiopathic interstitial pneumonia showed FVC differences of 46·5 mL (SE 39·9; 95% CI -32·5 to 125·5; p=0·25) at week 8 and 108·2 mL (46·9; 15·3 to 201·1; p=0·023) at week 16. Analysis of patients with idiopathic pulmonary fibrosis showed FVC differences of 84·5 mL (52·7; -20·4 to 189·5; p=0·11) at week 8 and 168·5 mL (64·5; 40·1 to 297·0; p=0·011) at week 16. The most frequent adverse events included cough, headache, dyspnoea, dizziness, nausea, fatigue, and diarrhoea. INTERPRETATION: In patients with ILD and associated pulmonary hypertension, inhaled treprostinil was associated with improvements in FVC versus placebo at 16 weeks. This difference was most evident in patients with idiopathic interstitial pneumonia, particularly idiopathic pulmonary fibrosis. Inhaled treprostinil appears to be a promising therapy for idiopathic pulmonary fibrosis that warrants further investigation in a prospective, randomised, placebo-controlled study. FUNDING: United Therapeutics Corporation.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Nathan SD, Waxman A, Rajagopal S, et al. Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. Lancet Respir Med. 2021. PMID: 34214475. doi:10.1016/S2213-2600(21)00165-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。